The Irish Medicines Board (IMB), now known as the Health Products Regulatory Authority (HPRA), is Irelandís regulator for medicines, medical devices, and clinical trials.
HPRA oversees clinical trial authorization, safety reporting expectations, and compliance activities for studies conducted in Ireland. For multinational trials, sponsors must align Irish regulatory requirements with broader global development plans and reporting workflows. HPRA expectations can influence submission timelines, documentation content, and safety escalation processes for Irish sites. Coordination helps maintain compliance while supporting efficient study startup and ongoing oversight.